BMEYE, a Dutch company based in Amsterdam, specializes in developing totally non-invasive ways of advanced hemodynamic monitoring. BMEYE's technology was developed by The Netherlands-based not-for-profit contract research institute TNO (Netherlands Organisation for Applied Scientific Research) to monitor the blood pressure of NASA astronauts in space.
In 2005, BMEYE was founded as a spin-off from TNO to develop the technology into clinical products. Today, BMEYE has two products approved for sale in the U.S. and Europe from this platform: Nexfin, for the Cardiology market, and ccNexfin, for the Anesthesia and Critical Care markets. These markets combined represent more than 25 million patients annually worldwide, with a total market opportunity of $1.5 billion.
Backed by over 30 years of research and development, BMEYE provides a unique non-invasive solution for the measurement of blood pressure and cardiac output - the next standard vital sign – as well as for other novel parameters for fluid responsiveness and oxygen delivery. Its monitors are safe, precise and easy to use, making advanced hemodynamic monitoring a reality in daily clinical practice.
BMEYE sets the standard and is the premier provider of non-invasive, beat-to-beat, user-friendly hemodynamic monitoring systems, to improve patient care and reduce healthcare costs.